Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.60, FiscalAI reports.
Cadrenal Therapeutics Stock Performance
Shares of CVKD traded up $0.06 during mid-day trading on Tuesday, reaching $1.46. The company had a trading volume of 6,698 shares, compared to its average volume of 183,493. Cadrenal Therapeutics has a 1-year low of $0.82 and a 1-year high of $12.50. The company has a market capitalization of $5.21 million, a price-to-earnings ratio of -0.29 and a beta of 1.94. The company’s 50 day simple moving average is $1.09 and its 200 day simple moving average is $3.61.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.00.
Get Our Latest Stock Analysis on Cadrenal Therapeutics
Cadrenal Therapeutics Company Profile
Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing treatments to prevent blood clots in people with cardiovascular conditions that require long-term anticoagulation. Its pipeline centers on tecarfarin, an investigational oral anticoagulant being developed as a potential alternative to warfarin. Tecarfarin is designed to be processed through a different metabolic pathway than warfarin and is being studied for patients with needs such as mechanical heart valves and end-stage renal disease.
Read More
- Five stocks we like better than Cadrenal Therapeutics
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
